论文部分内容阅读
本文检测了进展期胃癌患者（ｎ＝１６）脾静脉血淋巴细胞（ＳＶＬ）和脾细胞（ＳＣ）的自然杀伤细胞（ＮＫ）、淋巴因子激活的杀伤细胞（ＬＡＫ）的杀伤活性及Ｔ细胞（ＴＣ）亚群，与胃良性病变（ｎ＝７）的ＳＶＬ及外伤性脾破裂（ｎ＝６）的ＳＣ对照比较，探讨进展期胃癌（ＡＧＣ）患者脾脏的细胞免疫状态，为胃癌术中合理的处理脾脏提供免疫学依据。结果表明：ＡＧＣ患者脾脏的ＮＫ、ＬＡＫ细胞杀伤活性显著降低（Ｐ＜０．０２，Ｐ＜０．０１）；ＣＤ４显著减少，ＣＤ８显著增加，ＣＤ４／ＣＤ８比值显著降低（Ｐ＜０．０２～０．０１）。提示进展期胃癌患者脾脏的细胞免疫功能受到明显抑制。
This study examined the killing activity of natural killer cells (NK) and lymphokine-activated killer cells (LAK) in splenic venous lymphocytes (SVL) and spleen cells (SC) in patients with advanced gastric cancer (n=16) and T cells ( Comparison of subgroups of TC) with SC of benign gastric lesions (n=7) and SC of traumatic splenic rupture (n=6) to investigate the cellular immune status of spleen in patients with advanced gastric cancer (AGC), which is reasonable for intraoperative gastric cancer The treatment of the spleen provides immunological basis. The results showed that the killing activity of NK and LAK cells in the spleen of AGC patients was significantly lower (P<0.02, P<0.01); CD4 was significantly reduced, CD8 was significantly increased, and the CD4/CD8 ratio was significantly decreased (P<0.02- 0.01). It is suggested that the cellular immunity of spleen in patients with advanced gastric cancer is significantly inhibited.